Data as of Jan 30
| -1.71 / -4.49%|
The 9 analysts offering 12-month price forecasts for Tetraphase Pharmaceuticals Inc have a median target of 48.00, with a high estimate of 58.00 and a low estimate of 40.00. The median estimate represents a +32.01% increase from the last price of 36.36.
The current consensus among 10 polled investment analysts is to Buy stock in Tetraphase Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.